• HCC: Key topics discussed at ASCO GI & EASL 2022

  • Dec 6 2023
  • Duración: 13 m
  • Podcast

HCC: Key topics discussed at ASCO GI & EASL 2022

Escúchala gratis

Ver detalles del espectáculo

  • Resumen

  • Medical Education podcast by COR2ED. Professor James Harding, HCC Connect member, provides his perspectives and insights on key abstracts and topics discussed at ASCO GI 2022 and EASL liver cancer summit 2022 in hepatocellular carcinoma. He discusses the HIMALAYA study which evaluated dual immune checkpoint blockade inhibition namely, anti-CTLA-4 antibody tremelimumab with the anti-PD-L1 antibody durvalumab in the frontline setting with patients with unresectable hepatocellular carcinoma. There were other important studies at the meeting and Prof Harding highlights the RENOBATE study and the GOING study that evaluated nivolumab in combination with regorafenib and early addition of nivolumab to regorafenib regimen, respectively.
    Más Menos
Más Menos

Lo que los oyentes dicen sobre HCC: Key topics discussed at ASCO GI & EASL 2022

Calificaciones medias de los clientes

Reseñas - Selecciona las pestañas a continuación para cambiar el origen de las reseñas.

Reseñas de Audible.com

Opiniones de Amazon
No hay comentarios disponibles